Quest Diagnostics Inc vs Fubotv Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Fubotv Inc trades at $8.86 (market cap $1.02B). The key difference: Quest Diagnostics Inc is far larger — about 25× Fubotv Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Fubotv Inc for 35 Days on average.
| DGX | FUBO | |
|---|---|---|
Market Cap | $25.48B | $1.02B |
Volume | 941,866 | 978,631 |
Sector | Health | Media |
52-Week High | $247.45 | $48.96 |
52-Week Low | $173.49 | $8.09 |
Typical Hold Time | 56 Days | 35 Days |
Enterprise Value | $31.23B | $1.19B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
FUBO trades at $9.03, down 2.38% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M in 2025, representing a significant turnaround from previous losses. Recent developments include new sports streaming agreements with NHL teams and expanded partnerships with The Athletic, positioning the company for continued subscriber growth.
FUBO presents a compelling turnaround story with deep valuation discounts (P/E 2.43, P/S 0.19) and analyst consensus target of $63.38 suggesting 600%+ upside. However, risks include persistent cash flow challenges, high debt levels, and intense streaming competition. The Disney partnership and sports content expansion provide catalysts, but execution risk remains elevated given the company's history of losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →